| Literature DB >> 21684486 |
Waleed A Ismail1, Saleh A Al-Enzy, Saqer A Alsurayei, Ali E Ismail.
Abstract
Infliximab is a chimerical monoclonal antibody that inhibits pro-inflammatory activity of tumour-necrosis factor alpha (TNFα) and it is the primary biological agent used in the treatment of moderate-to-severe ulcerative colitis (UC). We report a case of vitiligo following infliximab administration in a patient with refractory UC. The case serves as a reminder of adverse cutaneous reactions induced by TNFα-antagonist therapy.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21684486 DOI： 10.1016/j.ajg.2011.03.001
Source DB: PubMed Journal: Arab J Gastroenterol ISSN： 1687-1979 Impact factor: 2.076